Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.S. administers 466.3 mln doses of COVID-19 vaccines - CDC

12/03/2021 | 03:25pm EST

Dec 3 (Reuters) - The United States has administered 466,348,132 doses of COVID-19 vaccines in the country as of Friday morning and distributed 580,893,145 doses, the U.S. Centers for Disease Control and Prevention said.

Those figures are up from the 464,445,580 vaccine doses the CDC said had gone into arms by Dec. 2 out of 578,263,565 doses delivered.

The agency said 234,743,864 people had received at least one dose while 198,211,641 people are fully vaccinated as of 6:00 a.m. ET on Friday.

The CDC tally includes two-dose vaccines from Moderna and Pfizer/BioNTech , as well as Johnson & Johnson's one-shot vaccine.

About 44.0 million people received a booster dose of COVID-19 vaccine from either Pfizer or Moderna or J&J. Booster doses from Moderna and Johnson & Johnson were authorized by the U.S. health regulator on Oct. 20.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Amy Caren Daniel)


ę Reuters 2021
All news about MODERNA, INC.
01/24Chile to purchase 2 million Moderna COVID-19 vaccine doses
RE
01/24LEIDEN UNIVERSITY : mRNA boosters are the most effective upon receiving Janssen vaccinatio..
AQ
01/24INSIDER SELL : Moderna
MT
01/24NORTH AMERICAN MORNING BRIEFING : Stocks Seen -3-
DJ
01/21Moderna's Valuation Has Come 'Back to Earth,' Become More Reasonable, BofA Securities S..
MT
01/21Boosters provide 'added protection' against Omicron -CDC
RE
01/21Small children getting less sick from Omicron; Genetic mutation protects against severe..
RE
01/21Booster shots needed against omicron, CDC studies show
AQ
01/21U.S. studies highlight the need for COVID boosters to fight Omicron
RE
01/21CDC : Vaccines less effective against Omicron, but still reduce risk for serious illness
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 644 M - -
Net income 2021 11 173 M - -
Net cash 2021 10 558 M - -
P/E ratio 2021 5,92x
Yield 2021 -
Capitalization 63 777 M 63 777 M -
EV / Sales 2021 3,02x
EV / Sales 2022 1,97x
Nbr of Employees 1 300
Free-Float -
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Last Close Price 157,30 $
Average target price 266,88 $
Spread / Average Target 69,7%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-38.07%63 777
LONZA GROUP AG-19.59%49 711
IQVIA HOLDINGS INC.-13.62%46 556
SEAGEN INC.-16.20%23 689
ICON PUBLIC LIMITED COMPANY-17.32%20 842
CELLTRION, INC.-15.91%19 358